



## **Dynavax to Present at CIBC World Markets and Acumen BioFin Rodman and Renshaw Healthcare Conferences**

BERKELEY, Calif., Nov 01, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced today Michael S. Ostrach, Vice President and Chief Business Officer, will present an overview of the company at two investor conferences in New York City the first week of November. Ostrach will present at the CIBC World Markets 18th Annual Healthcare Conference on Monday, November 5, 2007 at 8:35 a.m. ET (5:35 a.m. PT). In addition, Ostrach will present at the Acumen BioFin Rodman and Renshaw 9th Annual Healthcare Conference on Tuesday, November 6, 2007 at 4:45 p.m. ET (1:45 p.m. PT). Both presentations will be webcast.

To access the live audio broadcast and the subsequent archived audio recordings of the company presentation, please log onto the company's website at <http://www.dynavax.com> under the "Investors" section.

### About Dynavax

Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative TLR9 agonist-based products to treat and prevent infectious diseases, allergies, cancer, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our TLR9 agonists are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Our product candidates include: HEPLISAV(TM), a hepatitis B vaccine in Phase 3 partnered with Merck & Co. Inc.; TOLAMBA(TM), a ragweed allergy immunotherapy in Phase 2; a therapy for non-Hodgkin's lymphoma (NHL) in Phase 2 and for metastatic colorectal cancer in Phase 1; and a therapy for hepatitis B also in Phase 1. Our preclinical asthma and COPD program is partnered with AstraZeneca. The National Institutes of Health (NIH) partially funds our preclinical work on a vaccine for influenza. Symphony Dynamo, Inc. (SDI) funds our colorectal cancer trials and our preclinical hepatitis C therapeutic program, and Deerfield Management has committed funding for our allergy programs. While Deerfield, NIH and SDI provide program support, Dynavax has retained rights to seek strategic partners for future development and commercialization. For more information, please visit <http://www.dynavax.com>.

SOURCE Dynavax Technologies Corporation

<http://www.dynavax.com>

Copyright (C) 2007 PR Newswire. All rights reserved

News Provided by COMTEX